Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future by Riley, R D et al.
Reporting of prognostic markers: current problems and
development of guidelines for evidence-based practice
in the future
RD Riley*
,1, KR Abrams
1, AJ Sutton
1, PC Lambert
1, DR Jones
1, D Heney
2 and SA Burchill
3
1Department of Epidemiology and Public Health, University of Leicester, 22-28 Princess Road West, Leicester, LE1 6TP, UK;
2Department of Medical
Education, University of Leicester, University Road, Leicester, UK;
3Cancer Research UK Clinical Centre, St James’s University Hospital, Beckett Street,
Leeds, UK
Prognostic markers help to stratify patients for treatment by identifying patients with different risks of outcome (e.g. recurrence of
disease), and are important tools in the management of cancer and many other diseases. Systematic review and meta-analytical
approaches to identifying the most valuable prognostic markers are needed because (sometimes conflicting) evidence relating to
markers is often published across a number of studies. To investigate the practicality of this approach, an empirical investigation of a
systematic review of tumour markers for neuroblastoma was performed; 260 studies of prognostic markers were identified, which
considered 130 different markers.
The reporting of these studies was often inadequate, in terms of both statistical analysis and presentation, and there was
considerable heterogeneity for many important clinical/statistical factors. These problems restricted both the extraction of data and
the meta-analysis of results from the primary studies, limiting feasibility of the evidence-based approach.
Guidelines for reporting the results of primary prognostic marker studies in cancer, and other diseases, are given in order to
facilitate both the interpretation of individual studies and the undertaking of systematic reviews, meta-analysis and, ultimately,
evidence-based practice. General availability of full individual patient data is a necessary step forward and would overcome the
majority of problems encountered, including poorly reported summary statistics and variability in cutoff level, outcome assessed and
adjustment factors used. It would also limit the problem of reporting bias, although publication bias will remain a concern until studies
are prospectively registered. Such changes in practice would help important evidence-based reviews to be conducted in order to
establish the most appropriate prognostic markers for clinical use, which should ultimately improve patient care.
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Prognostic markers (also called prognostic variables or factors) are
relevant tools in the management of patients with cancer, and also
many other medical conditions, because they help to stratify
patients for treatment by identifying different risk groups in order
to reduce morbidity and mortality. They include biological,
clinical, genetic, histological and pathological features. For
example, carcinoembryonic antigen (CEA) is a prognostic marker
in colorectal cancer (Eche et al, 2001).
An evidence-based approach to identifying the most valuable
prognostic markers for a given disease is clearly important because
it is common for evidence relating to markers to be published
across a number of studies, often with conflicting results (Altman,
2001, pp 228–247; Riley et al, 2003a). Furthermore, a frequent
difficulty in assessing the clinical value of prognostic markers is
the relatively small number of patients in primary research studies,
sometimes a consequence of disease rarity and limited resources,
such that each primary study has low statistical power for
detecting any benefits of prognostic staging. The use of systematic
review, and in particular meta-analysis, methodology may there-
fore be important and allow a useful assessment of the prognostic
power of markers (Altman, 2001, pp 228–247). A systematic review
is the preferred means of identifying and combining existing
evidence (Egger et al, 2001). Meta-analysis is the statistical analysis
of the review, which seeks to combine all the relevant results found
from the literature identified in a quantitative way to produce
results more precise than is possible from the individual studies
(Sutton et al, 2000).
In this paper, we use a recently performed systematic review of
prognostic tumour markers studied in neuroblastoma to demon-
strate the problems encountered when using this approach, and
highlight how they limit evidence-based practice. We then
generalise the problems to other areas of oncology, and indeed
other disease settings, and ultimately provide specific guidelines
for reporting primary prognostic marker studies.
METHODS
Neuroblastoma is a neuroblastic tumour of the primordial neural
crest and is the most common extracranial solid tumour of
childhood. The study of prognostic markers for this disease forms
an active research area within which a large body of evidence
exists. This makes it an appropriate area for an empirical
Received 29 April 2002; revised 27 January 2003; accepted 29 January
2003
*Correspondence: Dr RD Riley; E-mail: rdr3@leicester.ac.uk
British Journal of Cancer (2003) 88, 1191–1198
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
C
l
i
n
i
c
a
linvestigation, and as such the problems identified in this study are
highly likely to generalise to other disease settings. A brief
description of the systematic review strategy adopted is now given.
Search strategy
The three on-line bibliographic databases Medline, Embase and
Cancerlit were chosen as a basis for identifying the relevant
literature from 1966 to February 2000. Papers written in a non-
English language were excluded. A full description of the search
strategy and inclusion/exclusion criteria is provided in Riley et al
(2003b). One investigator performed the assessment of the papers,
with second and third investigators independently checking a
sample of them. To be included in the review, a paper had to
provide a quantitative result or give tabulated individual patient
data evaluating the use of a tumour marker in neuroblastoma from
a primary research study of humans. To be classified as relevant to
prognosis, a paper had to present data, in the form of summary
statistics or individual patient data, relating tumour marker levels
at a measured point in time to the outcome of patients at the end of
a specific follow-up period. Owing to the large number of potential
markers, we focused on genetic/biological markers rather than
histological markers.
Data extraction for meta-analysis
From each of the papers included, information was extracted on
the tumour markers studied. Meta-analysis of those markers on
which eight or more papers provided data was considered. The
loge(hazard ratio) and its variance were the essential information
required from each study, as they provide an important
comparative estimate of the risk of death/disease recurrence
between two groups of patients. Furthermore, there are several
indirect estimation methods available when these statistics are not
directly reported (Parmar et al, 1998), and the loge(hazard ratio)
has an approximate normal distribution for large samples, making
it particularly amenable to meta-analysis techniques. We make the
assumption of proportional hazards throughout this paper.
It was common for a paper to report more than one prognostic
result by relating one or more markers to overall survival and/or
disease-free survival, and also by providing unadjusted and/or
adjusted results (e.g. adjusted for age, stage of disease). Estimates
of the loge(hazard ratio) and its variance comparing two groups
defined by a single marker level were sought from all the overall
survival and disease-free survival reports. An unadjusted estimate
was preferred for each as prior knowledge indicated that adjusted
results were likely to be highly inconsistent in the factors for which
adjustment was made (Altman, 2001, pp 228–247). An adjusted
estimate was sought in the absence of an unadjusted result.
Although some markers take only binary values (e.g. chromosome
1p – deletion or no deletion), it was also usual for primary studies
to dichotomise continuous variables using a cutoff level in order to
categorise patients into high- and low-risk groups.
A five-step sequential process (Figure 1) using 10 different direct
and indirect methods (Table 1), based on the approach of Parmar
et al (1998), was used in an attempt to obtain the loge(hazard ratio)
and its variance. Studies with samples smaller than 25 were not
included in Steps 2–5 because they were not considered large
enough to justify estimation methods. A more detailed version of
Figure 1 and a more in-depth description of the extraction
procedure are provided in Riley et al (2003b).
RESULTS
Literature search results
A total of 3415 papers were identified from the literature search.
After assessment, 260 papers were classified as ‘relevant’ to
prognosis, and these studied a total of 130 different tumour
markers for risk stratification of patients (for references see Riley
et al, 2003b).
Data extraction of prognostic marker results
The 13 most commonly studied prognostic markers were each
selected for an in-depth study to establish their individual value as
a prognostic tool (Table 2). Expression of CD44 gene was studied
in eight papers and the other 12 markers were studied in 10 or
more prognosis papers (Table 2). This involved 211 (81.2%) of all
the prognosis papers. Within these there were 575 reports of
prognostic power assessment where levels of any of these 13
tumour markers were related to overall survival or disease-free
survival by summary statistics or IPD.
Only 204 (35.5%) estimates of both the loge(hazard ratio) and its
variance could be calculated from Steps 1–5 using Methods 1–10
(Figure 1, Table 1). In particular, the loge(hazard ratio) and its
variance were both directly provided on only three occasions in the
575 reports (0.005%) (Table 1, Method 1), and all were from a
single paper (Berthold et al, 1997). Fortunately, individual patient
data were frequently presented within this literature, and from this
STEP 5
STEP 4
STEP 3
575 
451 
410 
27 
383 
8 
375 
4 
371 
No. of successes
at each step:
No. of estimates sought:
STEP 1
Extract direct estimates of loge(hazard
ratio) and its variance given, or apply 
Methods 3 − 9 (see Table 1) using
summary information explicitly provided  STEP 1
STEP 2
STEP 2
Use available individual patient data to
calculate an unadjusted estimate from a
Cox regression analysis
STEP 3
Apply Methods 5, 6, 8 or 9 to use a given
P-value or 2-statistic with other summary
information, at least one part of which
also needs estimating from figures or
tables in the paper in order to proceed 
124 
41 
STEP 4
Use Step 1 or 3 to obtain an adjusted
estimate for those cases where an
unadjusted estimate was not possible
from Steps 1− 3 but an equivalent
adjusted result was also presented
in the paper   
STEP 5
Use a survival curve to calculate an
indirect unadjusted estimate  
Total no. of successes = 204,
out of 575 possible (35.5%)
Figure 1 Methods and results at each stage of the sequential process
used to obtain a single direct or indirect estimate of the loge(hazard ratio)
and its variance for each of the reports where one of the 13 tumour
markers was related to overall or disease-free survival by summary statistics
or individual patient data across the literature. Five steps were used, with
unadjusted estimates sought primarily in each unless only an adjusted result
was available or otherwise stated.
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la further 41 direct estimates were made (Step 2, Method 2). The
remaining 160 successful estimates were obtained using Methods
3–10 (Table 1), the most frequently required of which used a
P-value/w
2-statistic in combination with group numbers and total
number of events, that is, deaths/recurrences of disease (102 times)
(Methods 8 and 9).
Problems limiting meta-analysis
Poor reporting of primary studies Primary studies of prognostic
tumour markers are clearly essential and we observed many
important results across the literature that have implications for
clinical practice. However, the general standard of reporting
primary studies was inadequate, and it was disappointing that we
only managed to obtain 35.5% of the estimates required despite the
intensive, time-consuming extraction procedure (Figure 1). This
hindered the use and interpretation of meta-analysis because we
could not incorporate the majority of results reported in the
literature and consequently introduced a strong potential for bias.
Among the 371 reports that did not enable estimates to be made,
there were five common reporting problems, most of which can be
simply addressed (Figure 2). Encouragingly, there was some
evidence that the reporting of prognostic markers has improved
over the last 10 years because all the papers that did provide a
hazard ratio or loge(hazard ratio) were published after 1990.
However, these papers still only represented approximately 17% of
the total literature identified over this period (i.e. only 26 out of
157 papers published after 1990 reported a hazard ratio).
Table 1 Description of the methods used to obtain estimates of the loge(hazard ratio) and its variance
Method Summary statistics or data required Step 1 Step 2 Step 3 Step 4 Step 5 Total
1 HR or loge(HR) and V 3 FF 0 F 3
2 Individual patient data F 41 FFF41
3 loge(HR) and CI 0 FF 1 F 1
4 HR and CI 30 FF 3 F 33
5 loge(HR) and P-value 2 F 02 F 4
6 HR and P-value 10 F 22 F 14
7 HR, group numbers and total events 2 FF 0 F 2
8 w
2-statistic, group numbers and total events 10 F 40 F 14
9 P-value, group numbers and total events 67 F 21 0 F 88
10 Survival curve FFFF 44
Total 124 41 27 8 4 204
The summary statistics required for each method are shown together with the number of times each method was successfully used in Steps 1–5 of the extraction process.
Methods 3–10 were used in order of preference shown. HR=hazard ratio; V=variance of the loge(HR); CI=confidence interval.
Table 2 Names of the 13 markers grouped by tumour marker class, with the number of prognosis papers identified for each, the number of reports when
it was related to either overall or disease-free survival by summary statistics or individual patient data, and the number of successful estimates made of the
loge(hazard ratio) and variance; evidence of heterogeneity is shown for outcome, cutoff levels, age, stage and adjustment factors
Marker class Marker name Papers
a
OS and DFS
reports
a
Total
successful
estimates
(w)
b
OS/DFS
successes
c
(i)
Different
cutoff
groups
d
(ii)
Different
stage
groups
d
(iii)
Different
age
groups
d U/A
e
Different
sets of
adjustment
factors
f
DNA or chromosome
abnormalities
MYC-N 151 194 94 48/46 9 9 4 77/17 16
DNA index 44 62 19 11/8 8 3 3 18/1 1
Chromosome 1p 40 49 20 11/9 1 5 2 18/2 2
Urinary catecholamines VMA 36 40 4 3/1 4 3 2 4/0 F
HVA 26 29 2 2/0 2 2 1 2/0 F
VMA:HVA 20 28 5 2/3 3 4 2 5/0 F
Dopamine 10 11 2 1/1 2 2 1 2/0 F
Biological markers CD44 8 8 3 0/3 1 1 2 3/0 -
TrkA 16 21 11 4/7 7 1 1 9/2 2
NSE 28 39 9 4/5 6 3 1 8/1 1
LDH 26 30 12 5/7 5 4 1 8/4 4
Ferritin 33 41 7 3/4 5 4 2 6/1 1
MDR 16 30 16 9/7 8 3 3 13/3 2
VMA=vanillylmandelic acid; HVA=homovanillic acid; NSE=neuron-specific enolase; MDR=multi-drug resistance protein; LDH=lactate dehydrogenase.
aNumber of papers
reporting prognostic marker results or IPD, with the overall no. of OS and DFS reports within them. There were 211 papers overall which reported overall survival (OS) and/or
disease-free survival (DFS) results or individual patient data (IPD) for one or more of the markers.
bNumber of OS and DFS reports for which successful estimates were
extracted.
cNumber of total successful estimates (c) by OS and DFS.
dThe total successful estimates (c) could also be grouped by those (i) using the same cutoff level (cutoff
includes a group for when it was ‘unknown’ (for an example see Table 3)); (ii) relating to patients with the same stages of disease (stages of disease groups were ‘unknown’ and
combinations of stages 1, 2, 3, 4, 4s); and (iii) relating to patients with the same age range (age groups were ‘all ages’, ‘o1 year’, ‘41 year’ and ‘unknown’). Columns 7–9 show the
number of different subgroups in each case.
eNumber of total successful estimates (c) that were unadjusted (U) and adjusted (A) (unadjusted estimates were preferred where
possible).
fNumber of successful adjusted estimates (A) that related to different sets of adjustment factors.
Prognostic markers and evidence-based practice
RD Riley et al
1193
British Journal of Cancer (2003) 88(8), 1191–1198 & 2003 Cancer Research UK
C
l
i
n
i
c
a
lHeterogeneity of clinical and statistical factors The synthesis of
our estimates was also restricted by the large variability in both
clinical and statistical factors. For each estimate of the loge(hazard
ratio) and its variance obtained, the cutoff level used to
dichotomise the continuous markers, stage of disease, age of
patients and outcome (overall or disease-free survival) were
recorded, and also whether the estimate was unadjusted or
adjusted and, if so, what adjustment factors were used. There
was great diversity in these features (Table 2). For example, for the
marker MYC-N there were 94 estimates of the loge(hazard ratio)
and variance obtained but these involved nine different cutoff
points, nine different stage groups, four different age groups, 77
unadjusted/17 adjusted estimates and two different outcomes
(Table 3). Furthermore, of the 17 estimates that were adjusted for
other prognostic markers or clinical features (using a Cox
regression model) only two were adjusted for exactly the same
set of factors, and these were from the same article (Maris et al,
2000).
This inconsistent and variable reporting was reflected equally in
the estimates obtained for the other 12 markers (Table 2). The type
of treatment of patients and the method of measuring the markers
were not recorded, but both would have added further hetero-
geneity to that observed.
Publication bias and reporting bias The common problem of
publication bias, and other reporting biases, may still affect our
data extraction; some results that do not generate formal
statistically significant or clinically valuable findings may not have
been published, because of a reluctance of journals to report or of
researchers to present negative findings. Such problems severely
limit the conclusions that can be drawn from meta-analyses
because not all the available evidence can be included, and
therefore the pooled results are likely to be biased. We investi-
gated the estimates obtained for MYC-N and indeed there did
appear to be evidence of publication bias, with a number of
studies with smaller hazard ratios considered to be missing (Riley
et al, 2003). This problem is likely to be closely related to the
Figure 2 Description of the key reporting problems that prevented
estimation of the loge(hazard ratio) and its variance in 371 (64.5%) of the
reports
Table 3 Heterogeneity in the 94 estimates of the loge(hazard ratio) and
its variance obtained for marker MYC-N
n
Outcome
DFS 46
OS 48
Result type
Unadjusted 77
Adjusted 17
Stage groups
All 68
12
32
44
1, 2, 3 3
1, 2, 3, 4 5
2, 3, 4, 4S 2
3, 4 3
Unknown 5
Cutoff point
1 copy 23
2 copies 1
3 copies 17
4 copies 5
5 copies 2
10 copies 18
Mean gene expression 2
Positive vs negative protein (or staining vs no staining) 9
Unknown 17
Age groups
All 78
o1 year 2
41 year 5
Unknown 9
OS=overall survival; DFS=disease-free survival.
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key problem 5).
Should we proceed with meta-analysis?
The poor reporting, potential for publication bias and, in
particular, the large heterogeneity across studies meant it was
practically impossible to perform reliable meta-analyses that
would determine the clinical importance of each marker studied.
Even the analysis of subgroups of estimates was not considered
realistic because it was virtually impossible to obtain subgroups
that reflected patients with similar features. For example, for
marker MYC-N there were 48 overall survival estimates obtained,
of which 41 were unadjusted, and 30 related to ‘all’ stages and ‘all’
ages. Furthermore, only eight of these 30 estimates related to the
most commonly used cutoff level of ‘1 copy number’, and there is
then the additional problem of heterogeneity for treatment used
and method of measuring the marker, not to mention the potential
impact of publication/reporting bias. The subgroup numbers were
even smaller for the other, less-studied markers; for example,
lactate dehydrogenase had only two unadjusted overall survival
estimates relating to the most common cutoff level (1500Ul
1)
and patients of ‘all’ ages and ‘all’ stages.
The only possible benefit of meta-analysis using the estimates
that we extracted is to highlight the results of previous studies and
help prioritise which markers should be studied in the future. We
take such an approach elsewhere (Riley et al, 2003b), but for the
purposes of this feasibility study it is clear that no firm clinical
policy decisions can be made from our evidence-based review.
DISCUSSION
Appraisal of the systematic review and data extraction
During the systematic review, we evaluated 3415 papers overall
and identified 260 with results from studies assessing the
prognostic power of tumour markers. This will have identified
the majority of the English-language literature, but inevitably some
papers will have been excluded unintentionally. However, it seems
plausible that the reporting in such papers, and equally non-
English papers, would be equally poor and heterogeneous.
We used the indirect methods suggested by Parmar et al (1998)
to increase the number of occasions an estimate of the loge(hazard
ratio) and its variance could be obtained. However, the estimates
they provide are only approximate and simply make the best
possible use of the results presented. Questions still exist about
how best to combine indirect estimates with direct estimates. For
this reason, we did not use other indirect methods. For example,
given further assumptions, we could have used estimates of the
proportion surviving to 2, 3, 5 or 10 years to obtain estimates of
the loge(hazard ratio) and its variance (Vale et al, 2002). However,
the papers were equally inadequate at presenting these survival
statistics. For example, in the 26 prognosis papers for the serum
marker lactate dehydrogenase, only 12 gave actuarial estimates of
the proportion surviving, and only six of these also gave a
confidence interval or standard error. They were also hetero-
geneous–five estimates were for overall survival, six were for
disease-free survival and one was unspecified; estimates were made
at 2, 3, 4 or 5 years. Further, very few reported numbers at risk
explicitly, as required for reliable estimation.
Generalisations to other prognostic markers
Although these reporting problems were observed for tumour
markers within the neuroblastoma literature, they have also
limited reviews in other paediatric cancers (Riley et al, 2003a),
and it seems plausible that the reporting will be equally poor for
prognostic markers in other areas of oncology, and indeed other
disease areas. Altman (2001, pp 228–247) discusses the potential
problems involved in systematic reviews of prognostic markers, in
particular that of poor and heterogeneous reporting of primary
studies. Cutoff points are frequently used to dichotomise
continuous markers and define groups, while different outcomes,
adjustment factors and groups of patients are common features
across prognostic studies. Inadequate reporting and presentation
of survival data has been shown to be a concern in the cancer
literature (Altman et al, 1995).
Reliable and clinically useful meta-analyses of observational and
nonrandomised studies, such as the majority of prognostic marker
studies, are generally difficult to perform (Fleiss and Gross, 1991).
Other recent systematic reviews of prognostic markers have
encountered similar problems to the ones we identified. Parker
et al (2001) performed a systematic review in prostate cancer to
establish whether age is a prognostic marker, but the incomplete
and heterogeneous nature of the reports prohibited any quanti-
tative overview. Similarly, a systematic review of prognostic
laboratory variables in patients with unresected colorectal liver
metastases was limited by the heterogeneity and poor quality of
individual studies (Friedburg et al, 2001). Zandbergen et al (2001)
performed a systematic review of biochemical markers of brain
damage for identifying poor outcome in anoxic-ischaemic coma,
but conclusions were limited by small sample sizes and different
cutoffs and/or laboratory techniques.
Meta-analyses of prognostic markers have been facilitated when
individual patient data were available (Look et al, 2002), in
particular to determine a consistent cutoff level (Sakamoto et al,
1996). For those investigators currently interested in performing a
quantitative review of prognostic markers, we recommend that
they consider asking authors for individual patient data and/or
the extra information they require, such as the loge(hazard ratio)
and its variance, as this approach is likely to be the most
productive.
Towards guidelines for improved reporting of prognostic
markers
It is clearly important that the quality of primary studies, and the
reporting of their results improve if clear conclusions and policy
recommendations are to be formed about prognostic markers.
Altman and Lyman (1998) have proposed important guidelines for
both conducting and evaluating prognostic marker studies,
including the need for prospective registration of studies. Along-
side these, we have developed simple guidelines on how to report
results to facilitate both interpretation of individual studies and
the undertaking of systematic reviews, meta-analysis and, ulti-
mately, evidence-based practice (Figure 3). Collaboration of
research groups is required to promote such practice and achieve
both the consistency and standards required. Ideally, both
summary data and individual patient data should be reported
according to our guidelines. It is important that time to event is
incorporated within prognostic marker analyses, and thus the
hazard ratio is preferred to other measures of relative risk such as
the odds ratio, which relates to a fixed time-point and ignores
censoring. However, in addition authors may wish to present the
more familiar actuarial % survival at n years preferably with a
confidence interval and the number of patients at risk at that time
in each group.
Benefits of individual patient data Although improved reporting
of summary statistics is very important, the availability of
individual patient data is the most viable way forward in order
to produce valid and clinically useful evidence-based reviews of
prognostic markers. Subject to any restrictions imposed by data
protection laws and guidelines, presentation or availability of full
individual patient data using our guidelines would overcome
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adjusted), outcome assessed (overall or disease-free survival) and
adjustment factors; the study of markers in subgroups of patients
(e.g. different ages, treatments) would also be easier. It would also
eliminate the problem of extracting estimates when inexact P-
values are presented, and would remove the need for arbitrary
extraction decisions when an individual study presents a marker’s
results for a range of cutoff values. Furthermore, if levels of all the
prognostic markers measured (even those producing nonsignifi-
cant results) are provided, then the problem of reporting bias
would be reduced. However, publication bias might still be a
concern if some studies are not published and do not make IPD
available; prospective registration of studies is therefore also
important to counteract this.
Individual patient data would also enable direct estimates of
the hazard ratio, and other statistics of interest, when data were
available but not used, analysed or presented properly in the
primary study. A total of 41 (20%) of the 204 estimates that we
obtained in the neuroblastoma review were direct estimates
calculated from individual patient data that would not have
otherwise been possible. It is clearly important to include
predominately direct estimates in any quantitative synthesis. In
fact, the potential for substantial differences in meta-analysis of
survival data when using results provided within the literature
instead of individual patient data has recently been shown in the
head and neck cancer literature (Duchateau et al, 2001). Individual
patient data would also allow model assumptions, for example
proportional hazards, to be checked as necessary, and enable the
baseline survival function to be estimated.
Presentation or availability of individual patient data would
permit more appropriate meta-analyses (Stewart and Parmar,
1993), and would further facilitate the identification of different
publications whose results relate to the same or overlapping set of
patients. It would also allow an evaluation of combinations of
markers, which may produce more specific and accurate
prognostic assessments. If it is not appropriate or feasible to
provide individual patient data within a paper itself, then there is
the opportunity to publish on the Internet (Hutchon, 2001). Of
course, even making individual patient data available on the web is
not without its problems, with the nonpermanency of individual
web-pages, and so perhaps a central repository to collate and
manage individual patient data is needed within each disease area.
The United Kingdom Children’s Cancer Study Group have already
initiated this type of approach within paediatric oncology (Mott
et al, 1997). Authors may also wish to state in their paper that the
IPD is available upon request (with contact details indicated) for
those requiring it for evidence-based reviews.
We acknowledge that there are additional issues that arise when
conducting individual patient data reviews (Stewart and Clarke,
1995), especially cost and time, but these have to be weighed
against the substantial problems we encountered. Of course, even
when prioritising the IPD approach, the meta-analyst will in
practice end up with a mixture of estimates obtained from IPD and
estimates obtained from summary statistics; hence, meta-analysis
methods that take these different sources into account are needed.
Cutoff levels The use of different cutoffs makes synthesis of results
particularly difficult. Of added concern is the possibility that the
choice of cutoff level in a report may be specifically chosen to
optimise the difference between the groups and produce a result
with the maximum statistical or clinical significance possible
(Altman et al, 1994; Altman and Lyman, 1998). If there is good
clinical reason to use a cutoff level, then it should be specified at the
start of a study and clearly reported within the results (Figure 3).
However, Altman (2001) suggests that continuous markers should
not be dichotomised because, among other reasons, this approach
discards potentially important quantitative information and
considerably reduces the power to detect a real association
between the marker and outcome. Hence, we encourage researchers
to analyse and report results (e.g. hazard ratio) of continuous
markers on their original continuous scale. Importantly, availability
of individual patient data including exact marker levels would
allow data to be reanalysed where cutoff levels were not consistent,
and also where continuous marker results were desired but
results using a cutoff level were given (or vice versa) (Figure 3).
Indeed, the most appropriate analysis of continuous prognostic
markers may require nonlinear modelling techniques, as highlighted
by Sauerbrei et al (1999); consultancy with statisticians or
others experienced with such techniques is recommended in this
situation.
Adjustment factors It is clear that once important prognostic
markers have been identified, they need to be evaluated against,
and also used in combination with, other known clinically useful
prognostic factors, such as clinical characteristics (e.g. age, stage of
Figure 3 Guidelines on how to report primary prognostic marker
studies in order to improve current reporting standards and allow clinically
useful evidence-based reviews to be made
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that are adjusted for other known prognostic factors will have the
greatest implications for clinical practice, and subsequently meta-
analyses of adjusted results are the necessity. However, if authors
are inconsistent in the sets of adjustment factors they use, it
becomes very difficult and impractical to pool results across
studies and make a proper evaluation of markers over and above
other factors. For the 17 adjusted MYC-N estimates, there were 16
different sets of adjustment factors, each containing one or more of
age, stage of disease, Shimada index, lactate dehydrogenase and
eight other prognostic markers. Individual study estimates of risk
(e.g. hazard ratio) can be influenced by which adjustment factors
are used (Rushton and Jones, 1992), and so there may be an
additional reporting bias concern if researchers specifically only
report those adjusted estimates with the most statistically
significant result.
We recommend that research groups collaborate and identify
the most commonly used prognostic tools in current practice, so
that adjusted results of new prognostic marker studies can use
consistent sets of adjustment factors. These identified prognostic
tools should also be presented within the available individual
patient data alongside the new markers being studied (Figure 2).
This would allow adjusted results to be calculated independently
across studies, using consistent sets of adjustment factors.
Prognostic indexes could also be calculated across studies and
evaluated in a meta-analysis if desired. Lambert et al (2002) have
shown that individual patient data are generally required when
investigating patient characteristics as effect modifiers in a meta-
analysis, and, for prognostic markers, our study shows that the
most valid and clinically useful meta-analysis results will only be
obtained from an individual patient data approach.
CONCLUSION
Prognostic markers are important tools in the management of
patients with cancer and many other diseases, and as such primary
studies of prognostic markers are essential. However, the design
and evaluation of such studies can be greatly improved (Altman
and Lyman, 1998). Furthermore, we have shown that a change in
how prognostic marker studies are reported is needed to provide
more effective and meaningful results, and also allow important
evidence-based reviews to be conducted. To facilitate such
improved reporting, we have attempted to compile guidelines
regarding how summary statistics and individual patient data
should be presented. In particular, the availability of full individual
patient data, including all markers considered, is the most
viable way forward to produce valid and clinically useful
evidence-based reviews and meta-analyses. Individual patient data
would limit the large problems of poor and heterogeneous
reporting that we observed, and also reduce the potential impact
of reporting bias. Prospective registration of studies alongside
the availability of IPD would also help restrict the potential for
publication bias. These guidelines all point to researchers working
together towards planned pooled analyses, currently a particularly
important concept for epidemiological research (Blettner et al,
1999).
Research groups within each disease area should be encouraged
to collaborate and facilitate these changes in practice; for example,
by defining a clear set of important adjustment factors and by
initiating central repositories to collate and manage individual
patient data. This move towards a more evidence-based approach
to the study and reporting of prognostic markers will help properly
establish the most appropriate individual, and potential combina-
tions of markers to be used in clinical practice, and should thereby
improve patient care.
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